BioMagnetic Solutions

BioMagnetic Solutions is a pioneering company specializing in ferrofluid-based technologies for cell selection, enhancing workflows in cell and gene therapy. Founded in 2012 in the US by Ted Liberti, BioMagnetic Solutions focuses on innovative solutions in cell separation technology. In January 2021, the company was acquired by Gamma Biosciences GP LLC, a portfolio company of KKR. During its history, it has successfully completed a total of 1 deal, with the most recent occurring on January 15, 2021.

BioMagnetic Solutions specializes in the development and commercialization of advanced cGMP (current Good Manufacturing Practice) ferrofluid-based cell selection technologies. Their core offerings enhance immunomagnetic cell separation workflows, which are critical in the fields of cell and gene therapy. The technology facilitates efficient and effective cell selection processes, integrating seamlessly into existing cellular manufacturing workflows. Key customers include clinicians, researchers, and manufacturers within the biopharma and life sciences sectors, who rely on these solutions to optimize their therapeutic and research outcomes.

BioMagnetic Solutions serves a global market, with its products available in North America, Europe, and select markets in Asia, reflecting its commitment to addressing the needs of diverse healthcare and research environments. BioMagnetic Solutions generates revenue through direct business transactions with its clients in the biopharma and life sciences sectors. The company's transactional structure includes partnerships and direct sales, focusing primarily on business-to-business (B2B) engagements. Clients purchase reagents and hardware, such as their proprietary streptavidin ferrofluid, under a structured pricing model that aligns with the needs of institutional buyers and research organizations.

These transactions facilitate the ongoing use of their innovative products in clinical and research applications, ensuring a steady revenue stream from repeat customers who integrate BioMagnetic Solutions' technologies into their operations. BioMagnetic Solutions plans to leverage its recent acquisition to expand its product line and enhance its market reach. The company aims to introduce new ferrofluid technologies designed for specific applications in cell therapy by the end of 2023. Additionally, BioMagnetic Solutions is targeting expansion into emerging markets in Asia and Latin America by 2024, capitalizing on the growing demand for advanced biopharma solutions in these regions.

The funding from the January 2021 acquisition will be instrumental in supporting product development and market entry strategies.